– Durable responses with median duration of CRc not reached in NPM1-m patients at ~15 months median follow-up – – Phase 3 KOMET-017 trial currently enrolling with potential for accelerated FDA review in 2028 – – Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Virtual Kura investor call on June 3 at 8:00 a.m. ET – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Ku ...